Beigene Stock News

BeiGene, Ltd. (NASDAQ:BGNE) CMO Jane Huang sold 1,500 shares of the firms stock in a transaction dated Wednesday, November 17th. The shares were sold at an average price of $381.34, for a total value of $572,010.00. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Jane Huang []

BeiGene (NASDAQ:BGNE) and Galecto (NASDAQ:GLTO) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, profitability and analyst recommendations. Analyst Recommendations This is a breakdown of recent recommendations and price targets for BeiGene and Galecto, as reported […]

BeiGene (NASDAQ:BGNE) and Galecto (NASDAQ:GLTO) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, profitability, risk, institutional ownership, analyst recommendations and dividends. Profitability This table compares BeiGene and Galectos net margins, return on equity and return on assets. Net Margins []

Fulton Bank N.A. bought a new position in shares of BeiGene, Ltd. (NASDAQ:BGNE) in the 3rd quarter, Holdings Channel reports. The fund bought 626 shares of the companys stock, valued at approximately $228,000. A number of other hedge funds and other institutional investors have also added to or reduced their stakes in BGNE. Capital International []

Bruton Tyrosine Kinase (BTK) Inhibitors Market Report for Forecast Period 2021-2027: The report presents the prevailing drivers, restraints, opportunities, and current trends in the Bruton Tyrosine Kinase (BTK) Inhibitors industry. The Bruton Tyrosine Kinase (BTK) Inhibitors Market report highlights in-depth

BeiGene, Ltd. (NASDAQ:BGNE)s share price gapped up before the market opened on Tuesday . The stock had previously closed at $382.37, but opened at $400.00. BeiGene shares last traded at $383.61, with a volume of 434 shares changing hands. BGNE has been the subject of several research reports. Sanford C. Bernstein initiated coverage on BeiGene []

Los Angeles, USA, Nov. 15, 2021 (GLOBE NEWSWIRE) -- Promising Treatment for Advanced Hepatocellular Carcinoma Enters Clinical Trials | DelveInsight There are a plethora of companies developing therapies to treat Advanced Hepatocellular Carcinoma. CStone Pharmaceuticals has its drug candidate in the most advanced stage (Phase III). DelveInsight''s " Advanced Hepatocellular Carcinoma Pipeline Insight " report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Hepatocellular Carcinoma pipeline landscapes. It comprises Advanced Hepatocellular Carcinoma pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Advanced Hepatocellular Carcinoma therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive Advanced Hepatocellular Carcinoma pipeline products. Some of the key takeaways from the Advanced Hepatocellular Carcinoma Pipeline Report Major companies such as CStone Pharmaceuticals, Akesobio, Chia Tai Tianqing Pharmaceutical Group, Yiviva Inc., BeiGene, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Carsgen Therapeutics, Ltd., Jiangsu Alphamab Biopharmaceuticals, Sunshine Lake Pharma Co., Ltd., AVEO Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd., Sinocelltech Ltd., LTD, Eureka Therapeutics Inc., Taizhou Hanzhong biomedical co.

BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, and NewBridge Pharmaceuticals, a specialty company in the Middle East and North Africa (MENA) regions established to bridge the access gap by partnering with global pharma and biotech companies,

CAMBRIDGE, Mass. & BEIJING & DUBAI, United Arab Emirates--(BUSINESS WIRE)---- $BGNE #BGNE--BeiGene and NewBridge Pharmaceuticals announce approval in Saudi Arabia of BRUKINSA® (zanubrutinib) in relapsed or refractory mantle cell lymphoma.

SYDNEY & CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene Announces BRUKINSA® (Zanubrutinib) Approved for Treatment of Patients with Mantle Cell Lymphoma

CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)---- $BGNE #BTKi--BeiGene (NASDAQ: BGNE; HKEX: 06160), a global, science-driven biotechnology company focused on developing innovative and affordable medicin

With recent updates from Pfizer Inc. ( PFE , Financial) and BioNTech SE ( BNTX , Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson's (

The stock price of BeiGene, a biotechnology company focused on developing molecularly targeted and immuno-oncology drug candidates, has seen a rise of 46% over the last twenty-one trading days, while

Beigene Ltd (NASDAQ: BGNE) shares are trading higher by 3.8% at $400 after the company announced it received a positive CHMP opinion for BRUKINSA for the treatment of adults with Waldenström's macro